GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReNeuron Group PLC (OTCPK:RNUGF) » Definitions » Short Percentage of Float

ReNeuron Group (ReNeuron Group) Short Percentage of Float


View and export this data going back to 2006. Start your Free Trial

What is ReNeuron Group Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of ReNeuron Group's Short Percentage of Float

For the Biotechnology subindustry, ReNeuron Group's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ReNeuron Group's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ReNeuron Group's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where ReNeuron Group's Short Percentage of Float falls into.


ReNeuron Group (ReNeuron Group) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReNeuron Group PLC (OTCPK:RNUGF) » Definitions » Short Percentage of Float
Comparable Companies
SLRX GLMD QRON ELOX APVO TSOI CNSP DRMA CWBR CPMV OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
RENE.GB:UK RENE:UK RQE1:Germany
Address
Pencoed Business Park, Pencoed, Bridgend, GBR, CF35 5HY
Website
https://www.reneuron.com
ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.